OBJECTIVE: The efficacy of double-filtration plasmapheresis (DFPP), combined with @entity1667 , to treat diffuse proliferative @entity1988 ( @entity1988 ) was studied. METHODS: Twenty-four @entity1 who were admitted to the hospital and diagnosed with diffuse proliferative @entity1988 ( @entity1988 Class IV-G(A)) through renal biopsy from 2011 to 2013 were recruited as the study subjects. The @entity1 ' clinical manifestations were @entity751 and/or @entity177 . The pathological features were @entity8 . The @entity1 were divided into two groups: the treatment group and the control group, with 12 @entity1 in each group. The @entity1 in the treatment group were first treated with DFPP combined with @entity1667 (0.8-1.0 mg/kg/day); subsequently, they were put on @entity1667 therapy only. The @entity1 in the control group were first put on @entity1667 pulse therapy (500-1,000 mg) for 3 days; subsequently, they were treated with @entity1667 (0.8-1.0 mg/kg/day) combined with @entity618 (1.5 g/day). The @entity1 were observed for 24 months. Levels of hemoglobin, platelet, albumin, serum @entity1011 , 24-h urinary protein, serum C3 , antinuclear antibody (ANA), anti-dsDNA, and anti-Smith were measured at 0, 3, 6, 12, and 24 months. Complete remission and recurrence standards were established. The total dosages of @entity1667 were calculated. Repeated renal biopsy was performed on several @entity1 . RESULTS: There was no statistical significance in the baseline conditions of the treatment and the control groups. For the treatment group, no plasmapheresis-related complications occurred. The two groups showed no significant difference in complete remission. The @entity1 ' @entity4 and @entity1143 resolved, urine volume, serum @entity1011 , and albumin levels returned to normal, urine protein decreased in treatment group more rapidly than the @entity1 in the control group. The mean dose of @entity1667 received in the treatment group was lower than in the control group. The @entity4417 levels in the treatment group were significantly higher than in the control group. The recurrence rate in the treatment group was lower than in the control group. Repeated renal biopsies on several @entity1 in the treatment group indicated that their pathology improved significantly, changing from @entity1988 (IV) to @entity1988 (II-III). CONCLUSIONS: Appropriate application of DFPP combined with glucocorticoid therapy could accelerate the remission of diffuse proliferative @entity1988 , reduce overall glucocorticoid dosage, prevent recurrence, and maintain C3 level in a higher level. J. Clin. Apheresis 31:375-380, 2016.    2015 Wiley Periodicals, Inc.

Therapeutic effect of double-filtration plasmapheresis combined with @entity1667 to treat diffuse proliferative XXXX .

@entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['glomerular diffuse proliferative lesions'] @entity1143 :: ('MESH:D010996', 'Disease') :: ['serous effusion'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity4417 :: ('718', 'Gene') :: ['complement C3'] @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis', 'LN'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity751 :: ('MESH:D013577', 'Disease') :: ['nephritic syndrome'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity1988 :: (MESH:D008181,Disease) :: ['lupus nephritis']
